Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
Trial ID or NCT#
To evaluate the overall survival of HLA-A*0201 positive adult patients with previously untreated advanced UM receiving IMCgp100 compared to Investigator's Choice of dacarbazine, ipilimumab, or pembrolizumab.
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma
Contact us to find out if this trial is right for you.
About this Clinical Trial
Your Message Will Go ToPhuong Pham
Go Back To The Trial